Meta‐analysis of observational studies and registries in RA, psoriasis and psoriatic arthritis patients suggest that those receiving TNF‐α blockers are at 30% lower risk (95% CI 0.54–0.90) of CVD than patients taking non‐biological therapies (Roubille et al.,2015), perhaps offering some support to the notion that TNF‐α blockade is efficacious in reducing CVD events in people with systemic inflammatory conditions. This evidence concerns the gene TNF and rheumatoid arthritis.